tradingkey.logo

BUZZ-Citi cuts PT on Pfizer as revenue flattens

ReutersJan 28, 2025 12:21 PM

Citi Research cuts PT on pharmaceutical giant Pfizer PFE.N to $29 from $30, citing stagnant revenue growth and policy changes

Brokerage says specialty care business will be affected by Inflation Reduction Act part D changes, which will affect how Medicare beneficiaries pay for prescription drugs

"While company is tightlipped on Danuglipron future, they are all in on obesity and continue to develop additional next gen molecules demonstrating continued interest," brokerage says

New PT represents 8% upside to stock's last close

PFE, set to release its Q4 earnings next week, beat adjusted EPS estimates for 15 straight quarters

12 of 26 brokerages rate stock "buy" or higher, 13 "hold" and 1 "sell" or lower; median PT is $31.5 - LSEG data

Stock fell 8% in 2024, compared with 23% increase in S&P 500 index .SPX

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI